Clinical trial 1479-0001
An open label, Phase I dose escalation trial, with dose confirmation and expansion, of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations.
Organ | Lung |
---|---|
Trial status | Trial open for recruitment |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 1 |
Academic trial | Non |
Sponsor | Boehringer Ingelheim |
EudraCT Identifier | 2020-004563-47 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04886804 |
Last update |